{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Type+II%3B+Diabetes&page=41",
    "query": {
      "condition": "Type II; Diabetes",
      "page": 41
    },
    "page_size": 10
  },
  "pagination": {
    "page": 41,
    "page_size": 10,
    "total_count": 3713,
    "total_pages": 372,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Type+II%3B+Diabetes&page=42&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Type+II%3B+Diabetes&page=40&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T10:13:46.940Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01377155",
      "title": "A Comparison of Two Initial Dosing Formulas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Insulin detemir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Diabetes Care Center",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2011-06",
      "completion_date": "2011-12",
      "has_results": false,
      "last_update_posted_date": "2013-08-27",
      "last_synced_at": "2026-11-19T10:13:46.940Z",
      "location_count": 1,
      "location_summary": "Salinas, California",
      "locations": [
        {
          "city": "Salinas",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01377155"
    },
    {
      "nct_id": "NCT03369626",
      "title": "Effectiveness of a Digital Therapeutic on Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Type2 Diabetes"
      ],
      "interventions": [
        {
          "name": "FareWell Program",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "FareWell",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 118,
      "start_date": "2017-07-26",
      "completion_date": "2018-02-28",
      "has_results": false,
      "last_update_posted_date": "2019-08-21",
      "last_synced_at": "2026-11-19T10:13:46.940Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03369626"
    },
    {
      "nct_id": "NCT02561078",
      "title": "An Administration Method Study of Human Regular U-500 Insulin (LY041001) in Participants With Type 2 Diabetes Mellitus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Human regular U-500 insulin (CSII)",
          "type": "DRUG"
        },
        {
          "name": "Human regular U-500 insulin (MDI)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 420,
      "start_date": "2015-10-20",
      "completion_date": "2017-05-09",
      "has_results": true,
      "last_update_posted_date": "2020-05-20",
      "last_synced_at": "2026-11-19T10:13:46.940Z",
      "location_count": 52,
      "location_summary": "Mobile, Alabama • Concord, California • Fresno, California + 48 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Concord",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "La Mesa",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02561078"
    },
    {
      "nct_id": "NCT00849849",
      "title": "Comprehensive Postpartum Screening Strategies for Women With Gestational Diabetes Mellitus (GDM)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Woman's",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 40 Years · Female only"
      },
      "enrollment_count": 214,
      "start_date": "2011-07",
      "completion_date": "2013-12",
      "has_results": false,
      "last_update_posted_date": "2014-12-18",
      "last_synced_at": "2026-11-19T10:13:46.940Z",
      "location_count": 1,
      "location_summary": "Baton Rouge, Louisiana",
      "locations": [
        {
          "city": "Baton Rouge",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00849849"
    },
    {
      "nct_id": "NCT00690638",
      "title": "Safety and Efficacy Study of Dutogliptin/PHX1149T to Treat Type 2 Diabetes Mellitus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "PHX1149T",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Phenomix",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 480,
      "start_date": "2008-07",
      "completion_date": "2010-04",
      "has_results": false,
      "last_update_posted_date": "2010-04-13",
      "last_synced_at": "2026-11-19T10:13:46.940Z",
      "location_count": 13,
      "location_summary": "Norwalk, California • Orange, California • Santa Ana, California + 10 more",
      "locations": [
        {
          "city": "Norwalk",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Santa Ana",
          "state": "California"
        },
        {
          "city": "Daytona Beach",
          "state": "Florida"
        },
        {
          "city": "Kissimmee",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00690638"
    },
    {
      "nct_id": "NCT01883258",
      "title": "Effect of Aerobic Interval Training on Cardiovascular Function in Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "High intensity aerobic interval training",
          "type": "OTHER"
        },
        {
          "name": "Continuous moderate intensity exercise",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "79 Years",
        "sex": "ALL",
        "summary": "30 Years to 79 Years"
      },
      "enrollment_count": 116,
      "start_date": "2013-05",
      "completion_date": "2018-07-16",
      "has_results": false,
      "last_update_posted_date": "2019-12-06",
      "last_synced_at": "2026-11-19T10:13:46.940Z",
      "location_count": 1,
      "location_summary": "Gainesville, Florida",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01883258"
    },
    {
      "nct_id": "NCT01778049",
      "title": "Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Background Metformin in Patient With Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "BI 10773",
          "type": "DRUG"
        },
        {
          "name": "BI 10773 Placebo",
          "type": "DRUG"
        },
        {
          "name": "BI 10773 / BI 1356",
          "type": "DRUG"
        },
        {
          "name": "BI 10773 / BI 1356 Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 708,
      "start_date": "2013-01",
      "completion_date": "2015-03",
      "has_results": true,
      "last_update_posted_date": "2016-04-04",
      "last_synced_at": "2026-11-19T10:13:46.940Z",
      "location_count": 24,
      "location_summary": "Chino, California • Huntington Beach, California • San Diego, California + 20 more",
      "locations": [
        {
          "city": "Chino",
          "state": "California"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Sylmar",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01778049"
    },
    {
      "nct_id": "NCT03367377",
      "title": "A Study of LY3209590 in Participants With Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "LY3209590",
          "type": "DRUG"
        },
        {
          "name": "Insulin Glargine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 70,
      "start_date": "2018-01-03",
      "completion_date": "2018-10-03",
      "has_results": false,
      "last_update_posted_date": "2018-12-11",
      "last_synced_at": "2026-11-19T10:13:46.940Z",
      "location_count": 2,
      "location_summary": "South Miami, Florida • High Point, North Carolina",
      "locations": [
        {
          "city": "South Miami",
          "state": "Florida"
        },
        {
          "city": "High Point",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03367377"
    },
    {
      "nct_id": "NCT00143247",
      "title": "Long-Term Safety Study of Inhaled Insulin: An Up to Four-Year Extension of Therapy in Subjects With Type 1 or Type 2 Diabetes Mellitus",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Exubera® (inhaled insulin)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 173,
      "start_date": "2003-03",
      "completion_date": "2008-01",
      "has_results": true,
      "last_update_posted_date": "2010-04-15",
      "last_synced_at": "2026-11-19T10:13:46.940Z",
      "location_count": 12,
      "location_summary": "San Diego, California • New Haven, Connecticut • Miami, Florida + 7 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Albuquerque",
          "state": "New Mexico"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00143247"
    },
    {
      "nct_id": "NCT02843399",
      "title": "Economic Outcomes of EQW (Exenatide Once Weekly) vs. IG (Insulin Glargine) in T2D Patients Who Are New to Injectable Therapy",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Diabetes Mellitus Type 2"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 15498,
      "start_date": "2016-08-15",
      "completion_date": "2016-12-15",
      "has_results": false,
      "last_update_posted_date": "2017-12-15",
      "last_synced_at": "2026-11-19T10:13:46.940Z",
      "location_count": 1,
      "location_summary": "Wilmington, Delaware",
      "locations": [
        {
          "city": "Wilmington",
          "state": "Delaware"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02843399"
    }
  ]
}